OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
A legfontosabb adatok
- Ki végzi
- M.D. Anderson Cancer Center
- Hol
- Houston (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2026. máj. 27.
- Várható befejezés
- 2030. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Systemic therapy
- A regiszteradat frissítve
- 2026. szeptember 15.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults who had a brain metastasis from NSCLC (a lung cancer) or melanoma fully removed by surgery. They will skip radiation to the surgery site and take drug therapy that works in the brain instead.
- Életkor
- 18 years or older
- Nem
- All sexes
- A betegség stádiuma
- A brain metastasis from NSCLC or melanoma, fully removed by surgery 5 weeks ago or less, with tissue tests confirming the cancer type. ECOG performance status of 2 or less (able to care for yourself). A brain tumor team must agree that radiation right after surgery can safely be skipped.
- Korábbi kezelés
- The removed tumor must never have had radiation. The cancer must not have grown during earlier treatment with the same drug type, and the last dose must be at least 6 months before the study drugs start. Planned study drugs: ipilimumab plus nivolumab for melanoma, osimertinib for EGFR-mutant NSCLC, or brigatinib, alectinib or lorlatinib for ALK-positive NSCLC.
- Biomarker vagy leletérték
- For NSCLC: an EGFR mutation (for example Exon 19 deletion or L858R) or an ALK rearrangement/fusion.
A részvétel fő kizáró okai
- Cancer known to have spread to the lining of the brain and spinal cord (leptomeningeal involvement)
- Past or planned whole brain radiotherapy
- Unacceptable side effects before from any of the planned study drugs
- Unable to have a brain MRI or MRI contrast
- Pregnancy or plans to become pregnant during the study
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki nem vehet részt
- Subjects that have previously received or are currently planned for whole brain radiotherapy
- Prior unacceptable toxicity on one or more of the agents comprising the planned study systemic therapy
- History of known leptomeningeal involvement (radiographic or cytological)
- Cognitively impaired subjects with a major medical, neurologic or psychiatric condition who are judged as unable to fully comply with study therapy or assessments should not be enrolled
- Participant unable to receive a brain MRI (implanted metal devices or foreign bodies) or MRI contrast
- Pregnancy or plans to become pregnant during the duration of the study
Egyéb feltételek
- Eligibility Criteria
- Age ≥ 18 years
- ECOG performance status ≤ 2
- Participants with a resected brain metastasis with gross total resection and pathologic confirmation of NSCLC or melanoma. Gross total resection must be confirmed based on a review of the operative report, pathology, and all post-operative images available at the time of enrollment
- Brain metastasis resection occurred ≤ 5 weeks ago
- Additional prior surgeries, including Laser Interstitial Thermal Therapy (LITT), to the same or nearby location are permitted, provided that residual disease or local recurrence is confirmed pathologically at the most recent resection
- The resected lesion has never previously been targeted by radiotherapy
- Evaluation by a brain metastasis multidisciplinary team (BM-MDT), consisting of a medical oncologist (can be the patient's primary medical oncologist), a radiation oncologist who regularly performs SRS, and a neurosurgeon, and agreement that the intracranial cavity does not or will not require immediate post-operative radiation (i.e. it is judged to be safe to omit post-operative radiation). This BM-MDT evaluation can take place in clinic or during a multidisciplinary conference, either before or after the surgical resection. If the BM-MDT evaluation was before the surgical resection, there can be no new findings in the interim (e.g. during or after the surgical resection) that would change the BM-MDT's recommendation, as determined by one or more of the patient's treating physicians
- Documentation by the patient's primary medical oncologist of a planned study systemic therapy regimen consisting of one of the following: dual-agent immune checkpoint inhibitors (e.g. ipilimumab and nivolumab) for melanoma, osimertinib for EGFR Mutant (e.g. Exon 19 deletion; L858R) NSCLC, and brigatinib, alectinib, or lorlatinib for ALK rearranged/fusion positive NSCLC. As new agents are approved, other highly-CNS active tyrosine kinase inhibitors for participants with NSCLC may be included at the discretion of the principal investigator
- For a participant with more than one recently resected brain metastasis that meets eligibility criteria #3-#7 above, it is permissible (but not mandated) for more than one surgical cavity to proceed without immediate post-operative radiation. All other intracranial disease must proceed with treatment according to standard-of-care practices at the time of enrollment. This may include treatment with SRS or observation if clinically appropriate
- Regarding prior systemic therapy:; For participants with melanoma: no prior disease progression on any immune checkpoint inhibitor agent and ≥ 6 months between the last dose of any immune checkpoint inhibitor agent and initiation of the study systemic therapy regimen; For participants with EGFR Mutant NSCLC: no prior disease progression on any EGFR-targeted tyrosine kinase inhibitor and ≥ 6 month between the last dose of any EGFR-targeted tyrosine kinase inhibitor and initiation of the study systemic therapy regimen; For participants with ALK rearranged/fusion positive NSCLC: no prior disease progression on any ALK-targeted tyrosine kinase inhibitor and ≥ 6 month between the last dose of any ALK-targeted tyrosine kinase inhibitor and initiation of the study systemic therapy regimen
- This study will allow non-English speaking subjects to be enrolled. Verbal Translation Preparative Sheet (VTPS) will be used if a translated consent form is not available in the subject's language. The consent form will be translated into the language of the subject after 2 or more occurrences. This will apply to any MD Anderson patient
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- MD Anderson Cancer CenterHouston, Egyesült ÁllamokContact: Thomas H Beckham, MDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
To remove a brain tumor, patients usually receive radiation to lower the chance that the cancer will come back in the spot where the tumor was removed.
A vizsgálat csoportja
- systemic therapyA vizsgált kezelés
* Begin CNS active systemic therapy as recommended by your oncologist within 5 weeks after surgery. * Attend study visits every 12 weeks during Years 1 and 2. * Participate in 4 neurocognitive function assessments in specific windows of time. * Beyond 2 years, your medical records will continue to be reviewed to look at your health status, unless the participant withdraw or are withdrawn earlier.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2026. szeptember 15.